Title : Possible involvement of PPARĪ³-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.

Pub. Date : 2013 Feb

PMID : 23149826






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Possible involvement of PPARgamma-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities. Nicotine peroxisome proliferator-activated receptor gamma Rattus norvegicus
2 Interestingly, the co-administration of peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, GW9662 (1 mg/kg/day, i.p., 2 weeks) submaximally, significantly prevented rosuvastatin-induced improvement in vascular endothelial integrity, endothelium-dependent relaxation, and nitrite/nitrate concentration in rats administered nicotine. Nicotine peroxisome proliferator-activated receptor gamma Rattus norvegicus
3 Interestingly, the co-administration of peroxisome proliferator-activated receptor gamma (PPARgamma) antagonist, GW9662 (1 mg/kg/day, i.p., 2 weeks) submaximally, significantly prevented rosuvastatin-induced improvement in vascular endothelial integrity, endothelium-dependent relaxation, and nitrite/nitrate concentration in rats administered nicotine. Nicotine peroxisome proliferator-activated receptor gamma Rattus norvegicus
4 Rosuvastatin prevents nicotine-induced vascular endothelial abnormalities by activating PPARgamma and endothelial NOS signaling pathways. Nicotine peroxisome proliferator-activated receptor gamma Rattus norvegicus